| Early-life hyperoxia-induced Flt3L drives neonatal lung dendritic cell expansion and proinflammatory responses. | Early-life hyperoxia-induced Flt3L drives neonatal lung dendritic cell expansion and proinflammatory responses.
Cui TX, Brady AE, Zhang YJ, Fulton CT, Goldsmith AM, Popova AP., Free PMC Article | 03/1/2023 |
| FLT3LG and IFITM3P6 consolidate T cell activity in the bone marrow microenvironment and are prognostic factors in acute myelocytic leukemia. | FLT3LG and IFITM3P6 consolidate T cell activity in the bone marrow microenvironment and are prognostic factors in acute myelocytic leukemia.
Chen H, Wu M, Xia H, Du S, Zhou G, Long G, Zhu Y, Huang X, Yang D., Free PMC Article | 10/8/2022 |
| Fast Maturation of Splenic Dendritic Cells Upon TBI Is Associated With FLT3/FLT3L Signaling. | Fast Maturation of Splenic Dendritic Cells Upon TBI Is Associated With FLT3/FLT3L Signaling.
Zhang J, Li Z, Chandrasekar A, Li S, Ludolph A, Boeckers TM, Huber-Lang M, Roselli F, Olde Heuvel F., Free PMC Article | 05/7/2022 |
| A new cytokine-based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia. | A new cytokine-based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia.
Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Godon C, Mahé B, Dubruille V, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Tessoulin B, Le Gouill S, Moreau P, Béné MC, Chevallier P., Free PMC Article | 07/24/2021 |
| Wild-type FLT3 and FLT3 ITD exhibit similar ligand-induced internalization characteristics. | Wild-type FLT3 and FLT3 ITD exhibit similar ligand-induced internalization characteristics.
Kellner F, Keil A, Schindler K, Tschongov T, Hünninger K, Loercher H, Rhein P, Böhmer SA, Böhmer FD, Müller JP., Free PMC Article | 05/1/2021 |
| FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia. | FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia.
Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P. | 08/22/2020 |
| the sFLc kinetic profile during induction appears to be a powerful early prognostic marker to take into account as it may help to classify AML patients better | FLT3 ligand plasma levels in acute myeloid leukemia.
Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P., Free PMC Article | 05/23/2020 |
| This study provides a platform for studying the in vivo effect of Flt3-L and GM-CSF on human DCs and regulatory T cells. | Introduction of Human Flt3-L and GM-CSF into Humanized Mice Enhances the Reconstitution and Maturation of Myeloid Dendritic Cells and the Development of Foxp3(+)CD4(+) T Cells.
Iwabuchi R, Ikeno S, Kobayashi-Ishihara M, Takeyama H, Ato M, Tsunetsugu-Yokota Y, Terahara K., Free PMC Article | 07/13/2019 |
| In both cohorts, the median Flt3L level was significantly higher at completion of each sequential modality than at baseline. The 5-year PFS (most events being metastatic progression) was 68% and 71% in the two cohorts consisting of 33% and 52% T4 cases. In the principal cohort, a high Flt3L level following the induction chemotherapy was associated with low risk for a PFS event (HR: 0.15; P < 0.01). | Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer.
Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR, Nielsen DL, Ree AH., Free PMC Article | 06/29/2019 |
| Levels of serum FLT3L are significantly decreased in SLE patients especially with lupus nephritis, compared to healthy controls. | Mesenchymal stem cell therapy induces FLT3L and CD1c(+) dendritic cells in systemic lupus erythematosus patients.
Yuan X, Qin X, Wang D, Zhang Z, Tang X, Gao X, Chen W, Sun L., Free PMC Article | 06/22/2019 |
| Increased serum levels of FLT3-L are markers of disease activity in patients with multiple myeloma. | Serum Levels of Soluble FLT3 Ligand in Patients with Active Multiple Myeloma Constitute Marker of Bone Marrow Plasma Cell Proliferative Activity.
Kokonozaki M, Kanellou P, Pappa CA, Vyzoukaki R, Sarantoulaki S, Stavroulaki E, Kyriakaki S, Alegakis A, Boula A, Alexandrakis MG. | 04/6/2019 |
| our study demonstrates that Flt3L acts as an important regulator of ILCs lymphopoiesis and it can be used as a tool to expand and study ILCs precursors in the BM. | Flt3 ligand expands bona fide innate lymphoid cell precursors in vivo.
Parigi SM, Czarnewski P, Das S, Steeg C, Brockmann L, Fernandez-Gaitero S, Yman V, Forkel M, Höög C, Mjösberg J, Westerberg L, Färnert A, Huber S, Jacobs T, Villablanca EJ., Free PMC Article | 11/17/2018 |
| The cytokine Fms-like tyrosine kinase 3 ligand is an important regulator of hematopoiesis. Its receptor, Flt3, is expressed on myeloid, lymphoid and dendritic cell progenitors and is considered an important growth and differentiation factor for several hematopoietic lineages. [review] | The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis.
Tsapogas P, Mooney CJ, Brown G, Rolink A., Free PMC Article | 03/10/2018 |
| Results elucidated a novel resistance mechanism that FL attenuated inhibitory effects of FLT3 inhibitors mainly through the activation of Wt-FLT3, not mutated FLT3 in acute myeloid leukemia. | Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells.
Chen F, Ishikawa Y, Akashi A, Naoe T, Kiyoi H., Free PMC Article | 01/6/2018 |
| it is likely that TGFbeta1 and FL, both abundantly produced by bone marrow stromal cells, function in a coordinated manner to render mixed-lineage leukemia gene-rearranged acute lymphoblastic leukemia cells chemoresistant | TGFβ1 synergizes with FLT3 ligand to induce chemoresistant quiescence in acute lymphoblastic leukemia with MLL gene rearrangements.
Tamai M, Furuichi Y, Kasai S, Ando N, Harama D, Goi K, Inukai T, Kagami K, Abe M, Ichikawa H, Sugita K. | 10/21/2017 |
| serum levels can be a marker of cutaneous manifestation in dermatomyositis and marker of microangiopathy in systemic sclerosis | Serum concentrations of Flt-3 ligand in rheumatic diseases.
Nakamura K, Nakatsuka N, Jinnin M, Makino T, Kajihara I, Makino K, Honda N, Inoue K, Fukushima S, Ihn H. | 09/10/2016 |
| Pre-treatment serum levels of FLT3-L were higher than controls. FLT3-L correlated positively with all soluble angiogenic factors, as well with bone marrow microvascular density. Post-treatment FLT3-L decreased significantly in responders to therapy. | Potential role of FLT3-ligand in the angiogenic process of multiple myeloma.
Kokonozaki M, Tsirakis G, Devetzoglou M, Kyriakaki S, Antonakis A, Vyzoukaki R, Pappa CA, Tzardi M, Alexandrakis MG. | 03/12/2016 |
| The immunohistochemical expression of caveolin-1 and podocalyxin in lungs from rats challenged with a 2-kDa macrophage-activating lipopeptide (MALP-2) and Flt3L, was examined. | Expression of caveolin-1 and podocalyxin in rat lungs challenged with 2-kDa macrophage-activating lipopeptide and Flt3L.
Tschernig T, Pabst R, Kasper M, El-Hadi M, Singh B. | 11/22/2014 |
| The Flt3L/CD135 axis is active in rheumatoid arthritis | FMS-related tyrosine kinase 3 ligand (Flt3L)/CD135 axis in rheumatoid arthritis.
Ramos MI, Perez SG, Aarrass S, Helder B, Broekstra P, Gerlag DM, Reedquist KA, Tak PP, Lebre MC., Free PMC Article | 11/8/2014 |
| Flt3L enhances global T cell and humoral immunity as well as both the numbers and antigen capture capacity of migratory dendritic cells and classical lymphoid-resident dendritic cells | Classical Flt3L-dependent dendritic cells control immunity to protein vaccine.
Anandasabapathy N, Feder R, Mollah S, Tse SW, Longhi MP, Mehandru S, Matos I, Cheong C, Ruane D, Brane L, Teixeira A, Dobrin J, Mizenina O, Park CG, Meredith M, Clausen BE, Nussenzweig MC, Steinman RM., Free PMC Article | 10/25/2014 |
| Administration of the hematopoietic growth factor Flt3L to human subjects increases the frequency and absolute number of Treg cells. | Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects.
Klein O, Ebert LM, Zanker D, Woods K, Tan BS, Fucikova J, Behren A, Davis ID, Maraskovsky E, Chen W, Cebon J. | 07/6/2013 |
| Human bone marrow stromal cells simultaneously support B and T/NK lineage development from human haematopoietic progenitors: a principal role for flt3 ligand in lymphopoiesis. | Human bone marrow stromal cells simultaneously support B and T/NK lineage development from human haematopoietic progenitors: a principal role for flt3 ligand in lymphopoiesis.
Nakamori Y, Liu B, Ohishi K, Suzuki K, Ino K, Matsumoto T, Masuya M, Nishikawa H, Shiku H, Hamada H, Katayama N. | 07/28/2012 |
| A novel dendritic cell(DC) progenitor regulatory pathway in which PGE(2) signaling through EP1/EP3 receptors regulates Flt3 expression and downstream STAT3 activation and survivin expression, required for optimal progenitor survival and differentiation. | Blockade of prostaglandin E2 signaling through EP1 and EP3 receptors attenuates Flt3L-dependent dendritic cell development from hematopoietic progenitor cells.
Singh P, Hoggatt J, Hu P, Speth JM, Fukuda S, Breyer RM, Pelus LM., Free PMC Article | 05/5/2012 |
| data demonstrate that the Flt3L/TK gene therapeutic approach can induce systemic immunological memory capable of recognizing a brain tumor neoantigen in a model of recurrent GBM | Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.
King GD, Muhammad AK, Larocque D, Kelson KR, Xiong W, Liu C, Sanderson NS, Kroeger KM, Castro MG, Lowenstein PR., Free PMC Article | 02/4/2012 |
| FLT3 ligand(FL) leads to further activation of FLT3 mutants and is especially important in light of recent findings of elevated FL levels in acute myeloid leukemia patients in response to chemotherapy. | Further activation of FLT3 mutants by FLT3 ligand.
Zheng R, Bailey E, Nguyen B, Yang X, Piloto O, Levis M, Small D., Free PMC Article | 11/12/2011 |